SCHEMBL3000851

SCHEMBL3000851

CC(C)C(C)(c1ccc(C#N)cc1)c1ccc(C(=O)Cc2ccccn2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 2/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ ALOX5AP P20292 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ HTT P42858 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ GSK3B P49841 1/20 0.38
▸ EPHX2 P34913 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ CXCR3 P49682 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ TRPM8 Q7Z2W7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13248549 0.82 RAB9A (0.50) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL13248358 0.79 ALOX5AP (0.53) ALDH1A1SMN1; SMN2ALOX5APCYP1A2KDM4E
SCHEMBL2998426 0.79 ALOX5AP (0.38) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL3002657 0.77 RAB9A (0.45) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL14009846 0.76 RAB9A (0.43) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL13268073 0.73 CYP17A1 (0.45) MEN1KMT2AALOX5APCYP1A2HTT
SCHEMBL3000149 0.73 ALOX5AP (0.56) RAB9ANPC1ALDH1A1SMN1; SMN2ALOX5AP
SCHEMBL3000832 0.73 ALOX5AP (0.56) ALDH1A1SMN1; SMN2ALOX5APKDM4EHPGD
SCHEMBL5949417 0.73 RAB9A (0.70) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL2998064 0.72 GRM5 (0.42) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2546232-A1 Diphenyl Substituted Alkanes Merck Sharp & Dohme Corp. (US) 2013-01-16 — — EP disclosed
EP-2546232-A1 Diphenyl Substituted Alkanes Merck Sharp & Dohme Corp. (US) 2013-01-16 — — EP disclosed
US-20100190761-A1 DIPHENYL SUBSTITUTED ALKANES MERCK SHARP & DOHME CORP. 2010-07-29 — — US disclosed
US-20100190761-A1 DIPHENYL SUBSTITUTED ALKANES MERCK SHARP & DOHME CORP. 2010-07-29 — — US disclosed
WO-2008156721-A1 DIPHENYL SUBSTITUTED ALKANES MERCK & CO., INC. (US) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190761-A1 DIPHENYL SUBSTITUTED ALKANES ALOX5, ALOX15, ALOX15B RAB9A 4316/4885NPC1 603/4885MEN1 4664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback